FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Guy Wendy 2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [ PCSA ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Administrative Officer
(Last)         (First)         (Middle)
C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106
3. Date of Earliest Transaction (MM/DD/YYYY)
7/8/2021
(Street)
HANOVER, MD 21076
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units  $0  7/8/2021    A     8572       (1)  (1) Common Stock  8572  $0  8572  D   
Restricted Stock Units  $0  7/8/2021    A     12858       (2)  (2) Common Stock  12858  $0  12858  D   
Restricted Stock Units  $0  7/8/2021    A     1907       (3)  (3) Common Stock  10034  $0  10034  D   

Explanation of Responses:
(1)  The restricted stock units vest in two equal installments beginning July 1, 2022.
(2)  The Restricted Stock Units vest upon achievement of certain performance goals.
(3)  Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Guy Wendy
C/O PROCESSA PHARMACEUTICALS, INC.
7380 COCA COLA DRIVE, SUITE 106
HANOVER, MD 21076


Chief Administrative Officer

Signatures
/s/ Wendy Guy by Michael B. Kirwan, as Attorney-in-Fact 7/9/2021
**Signature of Reporting Person Date
Processa Pharmaceuticals (QB) (USOTC:PCSA)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Processa Pharmaceuticals (QB) Charts.
Processa Pharmaceuticals (QB) (USOTC:PCSA)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Processa Pharmaceuticals (QB) Charts.